Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort.
Rafaela PirolliViviane Teixeira Loiola de AlencarFelipe Leonardo EstatiAdriana Regina Gonçalves RibeiroDaniella Yumi Tsuji HondaMariana de OliveiraJoao Paulo da Silveira Nogueira LimaElizabeth Santana Dos SantosAndrea Paiva Gadelha GuimarãesGlauco BaiocchiAlexandre Andre Balieiro Anastacio da CostaPublished in: BMC cancer (2021)
Our retrospective study has shown superior PFS of ddCT over CT regimen in first-line treatment of ovarian carcinoma in a Western population not treated with bevacizumab.